ArticleFrontiers in immunology2026
Clinical, hematologic, and inflammatory factors associated with psoriatic arthritis in a Chinese hospital-based study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriatic arthritis (PsA) develops in up to approximately 30% of patients with psoriasis (PsO) and can cause irreversible joint damage. For dermatologists, identifying factors independently associated with PsA may help identify patients who may benefit from earlier musculoskeletal monitoring and specialist referral. Objective: To identify demographic, clinical, and laboratory factors independently associated with clinical and subclinical PsA in patients with psoriasis. Methods: This retrospective study at Shandong Provincial Hospital included 75 clinical PsA, 22 subclinical PsA, and 95 PsO patients. Subclinical PsA was applied as an operational label only: 21 of these 22 patients met the symptom-based criterion alone and 1 met both the symptom-based and imaging-based criteria. Separate multivariable logistic regression models were fitted for clinical PsA versus PsO and subclinical PsA versus PsO, checked for multicollinearity, with C-reactive protein (CRP) log-transformed and platelet (PLT) count expressed per 50×10 Results: In clinical PsA, lower hemoglobin (adjusted OR 0.75 per 10 g/L increment), higher PLT count (adjusted OR 1.39 per 50×10 Conclusion: Lower hemoglobin and elevated CRP were consistently associated with PsA across both subgroups. Routine hematologic and inflammatory markers, combined with musculoskeletal ultrasound (MSUS), may help dermatologists identify psoriasis patients warranting earlier rheumatological referral; prospective studies are needed to confirm predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.